Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. et al. (17-cv-11008).

  • November 3, 2017

Janssen Biotech brought this case asserting infringement of a patent related to the manufacture of Remicade 00ae, a biologic medicine used to treat rheumatoid arthritis, plaque psoriasis, Crohn 2019s disease, and other disorders involving the immune response. Celltrion moved to dismiss, on the grounds that not all co-owners of the patent were joined as plaintiffs 2013 the assignments from some of the inventors was to 201cthe COMPANY, 201d which was defined elsewhere in the assignment agreement as Centocor, the predecessor to Janssen, and Johnson & Johnson and its existing and future subsidiaries, divisions and affiliates, none of whom were named as plaintiffs. Judge Wolf, interpreting the agreement under New Jersey law, found that this language did not apply to the assignment itself. The assignment clause required assignment of any invention made by the employee 201cduring [his] employment with the COMPANY; 201d yet the inventors worked for only one company and did not work for Johnson & Johnson, which created ambiguity as to what was meant. Looking to extrinsic evidence to understand what the parties to the contract intended, Judge Wolf determined that the assignment was intended to be only to Centocor, making Janssen the sole assignee. Accordingly, the motion to dismiss was denied.

By submitting this form, you are consenting to receive marketing emails from: Lando & Anastasi, LLP. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact


How can we help you?